Market Closed -
Bombay S.E.
03:30:56 21/05/2024 pm IST
|
5-day change
|
1st Jan Change
|
165.9
INR
|
-3.49%
|
|
-0.51%
|
-4.38%
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
377.7
|
553.2
|
274.3
|
2,545
|
2,563
|
1,471
|
Enterprise Value (EV)
1 |
674.7
|
794.5
|
400.1
|
2,485
|
2,589
|
1,510
|
P/E ratio
|
-11.8
x
|
8.06
x
|
3.25
x
|
14.9
x
|
24.7
x
|
35.6
x
|
Yield
|
-
|
1.38%
|
4.17%
|
1.35%
|
1.34%
|
1.56%
|
Capitalization / Revenue
|
0.39
x
|
0.4
x
|
0.21
x
|
2.01
x
|
1.92
x
|
1.04
x
|
EV / Revenue
|
0.69
x
|
0.58
x
|
0.31
x
|
1.96
x
|
1.94
x
|
1.07
x
|
EV / EBITDA
|
21.2
x
|
4.81
x
|
2.56
x
|
8.8
x
|
14
x
|
15.2
x
|
EV / FCF
|
-14.2
x
|
32.1
x
|
4.23
x
|
17.8
x
|
-42.2
x
|
37
x
|
FCF Yield
|
-7.02%
|
3.11%
|
23.6%
|
5.63%
|
-2.37%
|
2.71%
|
Price to Book
|
1.3
x
|
1.52
x
|
0.65
x
|
4.21
x
|
3.82
x
|
2.16
x
|
Nbr of stocks (in thousands)
|
11,446
|
11,446
|
11,446
|
11,446
|
11,446
|
11,446
|
Reference price
2 |
33.00
|
48.33
|
23.97
|
222.3
|
224.0
|
128.5
|
Announcement Date
|
24/07/18
|
05/07/19
|
19/08/20
|
24/06/21
|
13/07/22
|
12/07/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
973.4
|
1,374
|
1,311
|
1,265
|
1,334
|
1,410
|
EBITDA
1 |
31.81
|
165.3
|
156.1
|
282.4
|
184.3
|
99.34
|
EBIT
1 |
-7.751
|
124.9
|
115.6
|
245.9
|
144.5
|
53.62
|
Operating Margin
|
-0.8%
|
9.09%
|
8.82%
|
19.44%
|
10.83%
|
3.8%
|
Earnings before Tax (EBT)
1 |
-46.84
|
97.57
|
120.9
|
240.6
|
137.7
|
44.94
|
Net income
1 |
-32.13
|
68.62
|
84.47
|
171.1
|
103.8
|
41.31
|
Net margin
|
-3.3%
|
4.99%
|
6.44%
|
13.52%
|
7.78%
|
2.93%
|
EPS
2 |
-2.807
|
5.993
|
7.380
|
14.95
|
9.070
|
3.609
|
Free Cash Flow
1 |
-47.38
|
24.74
|
94.5
|
139.9
|
-61.4
|
40.87
|
FCF margin
|
-4.87%
|
1.8%
|
7.21%
|
11.06%
|
-4.6%
|
2.9%
|
FCF Conversion (EBITDA)
|
-
|
14.97%
|
60.55%
|
49.56%
|
-
|
41.14%
|
FCF Conversion (Net income)
|
-
|
36.06%
|
111.88%
|
81.79%
|
-
|
98.93%
|
Dividend per Share
|
-
|
0.6667
|
1.000
|
3.000
|
3.000
|
2.000
|
Announcement Date
|
24/07/18
|
05/07/19
|
19/08/20
|
24/06/21
|
13/07/22
|
12/07/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
297
|
241
|
126
|
-
|
25.3
|
39.5
|
Net Cash position
1 |
-
|
-
|
-
|
59
|
-
|
-
|
Leverage (Debt/EBITDA)
|
9.335
x
|
1.459
x
|
0.8058
x
|
-
|
0.137
x
|
0.3974
x
|
Free Cash Flow
1 |
-47.4
|
24.7
|
94.5
|
140
|
-61.4
|
40.9
|
ROE (net income / shareholders' equity)
|
-10.5%
|
21%
|
21.4%
|
33.2%
|
16.3%
|
6.11%
|
ROA (Net income/ Total Assets)
|
-0.57%
|
8.39%
|
7.66%
|
17.1%
|
10.1%
|
3.47%
|
Assets
1 |
5,660
|
817.7
|
1,103
|
999.5
|
1,031
|
1,191
|
Book Value Per Share
2 |
25.40
|
31.80
|
37.10
|
52.80
|
58.70
|
59.50
|
Cash Flow per Share
2 |
1.510
|
0.5800
|
0.5600
|
14.10
|
0.4900
|
0.5100
|
Capex
1 |
38.4
|
49.6
|
46.9
|
39
|
65.5
|
94.7
|
Capex / Sales
|
3.95%
|
3.61%
|
3.58%
|
3.08%
|
4.91%
|
6.71%
|
Announcement Date
|
24/07/18
|
05/07/19
|
19/08/20
|
24/06/21
|
13/07/22
|
12/07/23
|
|
1st Jan change
|
Capi.
|
---|
| -4.38% | 2.36Cr | | +22.35% | 4.41TCr | | +22.22% | 2.26TCr | | +17.41% | 1.51TCr | | +15.73% | 1.36TCr | | +57.91% | 1.33TCr | | -8.98% | 693.96Cr | | -0.05% | 678.76Cr | | +15.65% | 575.2Cr | | -8.87% | 572.55Cr |
Generic Pharmaceuticals
|